Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights

Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

Fortress Biotech’s Cyprium enters agreement to sell PRV for $205M

UPDATE: Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million

Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Less Than A Year Away From Profitability

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO® (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States